Nanobac Pharmaceuticals Inc. Announces Investor Conference Call, Hosted by John Stanton, Chairman
Thursday November 9, 3:07 pm ET
Dr. Benedict S. Maniscalco, Head of Research & Development, to Give Detailed Update on Nanobac Discoveries
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News) announces it will host an investor conference call on Thursday, November 16, 2006, to begin at 4:15 P.M. Eastern Time.
In discussing the conference call, John Stanton, Chairman of Nanobac Pharmaceuticals Inc., stated, "We are thrilled with the recent preliminary results we are obtaining at Nanobac bringing new scientific support to earlier findings that the pathophysiology of calcification in vascular and other organ systems involving calcifying nanoparticles.
"Our scientific team has been working diligently on our previously announced research initiatives. In an effort to explain our latest discoveries, Dr. Maniscalco will give a detailed description of the recently released video of decalcifying Calcifying Nanoparticles (CNPs) as well as the status of all of our research initiatives. We have a commitment to our shareholders as well as the investment community for high level disclosure and communication. We look forward to updating interested parties on recent developments."
To hear the conference call as it takes place:
Call 800-391-2548 in the United States or;
Call 866-627-1646 in Canada or;
Call 302-709-8328 Internationally
Verbal Passcode: VT18107
To hear a recording of the call (available for 30 days
following the conference call):
Call 800-355-2355 in the United States;
Call 402-220-2946 in Canada or Internationally
Pin Code: 18107
About Nanobac Pharmaceuticals:
Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News) is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies, and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit nanobac.com.
Multimedia Available: businesswire.com
Contact:
For Nanobac Pharmaceuticals, Tampa
Redwood Consultants, LLC
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc. |
